Drug Trial Radar · NCT07897227
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6062 in Patients With Advanced Solid Tumors.
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
May 1, 2029
Study completion Nov 1, 2029
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, open-label, dose-escalation, PK expansion, and cohort expansion, first-in-human phase I/II study to evaluate the safety, tolerability, PK profile, and preliminary antitumor efficacy of SYS6062, a CEACAM5-targeted antibody-conjugate drug, in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumors
- Gastric Cancer (GC)
- Colorectal Cancer (CRC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
SYS6062Biological
Intravenous infusion will be administered until disease progression or intolerable toxicity
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs) and serious adverse events (SAEs)Time frame: Up to 3 years
- Dose-limiting toxicities (DLTs)Time frame: Up to approximately 1 year
- Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)Time frame: Up to approximately 1 year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.